Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Subjects Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cycling, Running, and Playing Rugby on Three Biomarkers That May Indicate Brain Injury

NCT06804291
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Running, Cycling, Rugby, control group
Other
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

NCT01681290
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
CBX129801
Drug
Lead sponsor
Cebix Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Escondido, California • Fresno, California • Irvine, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

NCT03136991
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD4831, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 19, 2026, 9:28 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
Diranersen, Diranersen-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

NCT03445013
View directory record Official record
Conditions
Psoriasis
Interventions
SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Boise, Idaho • Austin, Texas • College Station, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

NCT04149860
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
Lu AF87908, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
6
States / cities
Glendale, California • Hollywood, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 19, 2026, 9:28 AM EDT
Not listed Phase 2 Interventional

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Results available

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

NCT00847886
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LX3305, LX3305 Placebo, Methotrexate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

NCT00431964
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin 250 mg tablets, placebo tablets
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
6 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 19, 2026, 9:28 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Real-time Adaptation to Changes in Insulin Sensitivity

NCT01261052
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

NCT01284387
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 (vanutide cridificar)
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability

NCT03329014
View directory record Official record
Conditions
Procedural Sedation
Interventions
Remimazolam, Placebo
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery

NCT02713230
View directory record Official record
Conditions
Pain
Interventions
bupivacaine liposome injectable suspension, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Mobile, Alabama • Englewood, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

NCT03818607
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
ABP 959, Eculizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

NCT03301298
View directory record Official record
Conditions
Healthy
Interventions
SXC-2023, Placebo oral capsule
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Not applicable Interventional Results available

A Registry Study to Evaluate Outcomes of PEMF Therapy in Subjects With Various Pain Etiologies

NCT02881112
View directory record Official record
Conditions
Pain
Interventions
Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bradenton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

NCT00422981
View directory record Official record
Conditions
Mild Cognitive Impairment, So Stated
Interventions
AL-108, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
55 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Peoria, Arizona • Garden Grove, California • National City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

NCT02332798
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-04958242, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00662909
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
109
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 19, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

NCT01421498
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Waterbury, Connecticut • Louisville, Kentucky • Augusta, Maine + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 19, 2026, 9:28 AM EDT
Not listed Not applicable Interventional

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

NCT03953963
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance
Interventions
HydraSolve T2D™
Device
Lead sponsor
Medality Medical
Industry
Eligibility
22 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 19, 2026, 9:28 AM EDT